Bellicum battles on despite share-shattering setback for lead therapy

1 February 2018

Shares in US cell therapy specialist Bellicum Pharmaceuticals (Nasdaq: BLCM) were worth more than a quarter less on Thursday morning than they were on Tuesday.

The drop to below $6 came about after the US Food and Drug Administration (FDA) placed a clinical hold on studies going on in the USA of BPX-501, Bellicum’s lead therapy, following three cases of brain damage which could be related to the treatment. The patients were taking the drug to support allogeneic stem cell transplants.

But Bellicum is continuing with its ongoing European BP-004 registration trial of BPX-501, which is being investigated in children with hematological cancers or orphan inherited blood disorders in which BPX-501 is administered after initial allogeneic haploidentical stem cell transplantation (HSCT).

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK